Telemedicine Is Fastest Growing Segment Fueling The Growth Of The Global Candidiasis Market
![]() |
Candidiasis Market |
The global Candidiasis Market is
estimated to be valued at US$ 984.80 Mn
in 2023 and is expected to exhibit a CAGR
of 3.2% over the forecast period 2023 to 2030, as highlighted in a new
report published by Coherent Market Insights.
Market Overview:
Candidiasis refers to infections
caused by yeasts of the genus Candida. Candida infections can appear in the
mouth, throat, esophagus, vagina, or other parts of the body. Signs and
symptoms depend on the specific site of infection. Treatment involves
over-the-counter antifungal medication or prescription antifungal medication.
Market key trends:
One of the key trends in the
candidiasis market is the rise in telemedicine. With the ongoing covid-19
pandemic, telemedicine emerged as an effective way for patients to consult
doctors virtually and receive medical guidance without physically visiting
hospitals and clinics. This reduced the risk of exposure to infections. Online
consultations helped identify patients suffering from candidiasis and recommend
appropriate treatment measures. The increased adoption of telemedicine
solutions during the pandemic has highlighted its benefits and boosted its
usage even in the post-pandemic period. This is expected to drive the growth of
the candidiasis market during the forecast period.
Segment Analysis
The global candidiasis market is
segmented based on drug type, indication, distribution channel, and region. By
drug type, the market is divided into azoles, echinocandins, and others. The
azoles segment accounts for the largest market share, owing to the high
prescription rates of drugs such as fluconazole for oral and vaginal
candidiasis. By indication, the market is classified into vulvovaginal
candidiasis, oral candidiasis, cutaneous candidiasis, and others. Vulvovaginal
candidiasis is the dominant segment due to the high prevalence of yeast
infections, especially among women. By distribution channel, the market is
bifurcated into hospital pharmacies and retail pharmacies & drug stores.
Hospital pharmacies dominate the segment due to the high volume of candidiasis
drug prescriptions in inpatient settings.
Key Takeaways
The Global
Candidiasis Market Size is expected to witness high growth, exhibiting CAGR of 3.2% over the forecast period,
due to increasing prevalence of chronic conditions requiring immunosuppressive
therapy.
Regional analysis: North America accounts for the largest share of
the global candidiasis market, followed by Europe. This is attributed to the
rising incidence of fungal infections, growth in research activities, and
availability of advanced treatment options in these regions. However, Asia
Pacific is expected to exhibit the highest CAGR during the forecast period
owing to growing patient awareness, increasing healthcare spending, and
improving healthcare infrastructure in countries such as China and India.
Key players: Key players operating in the candidiasis market are
Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm
Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc.,
among others. Astellas Pharma and Pfizer hold a major market share due to their
branded drug portfolio and global commercialization footprint.
Get More Insights Here
https://www.newsstatix.com/candidiasis-market-size-share-growth-outlook-2023/
Comments
Post a Comment